Five children with cystic fibrosis complicated by hepatic cirrhosis received liver grafts. They all had portal hypertension with varices and three had variceal bleeding; respiratory function was only moderately impaired, but four were colonised with pseudomonas and one with aspergillus. Liver transplantation was well tolerated and there was no increase in respiratory or other early postoperative complications. Four of the children were fully well from 14 to 35 months after transplantation; the most recently transplanted had problems from a biliary stricture. In spite of the need for immunosuppression there was no increase in infection and respiratory fimction improved or remained stable. Once the children were stabilised after transplantation their nutrition and general health were greatly improved.
In patients with cystic fibrosis improved management of the lung problems has increased life expectancy and more patients now develop extrapulmonary complications.'
Hepatic cirrhosis occurs in up to 25% of children with cystic fibrosis and may progress to severe portal hypertension.2 This problem usually presents within the first 10 years of life with hepatosplenomegaly, but only mild derangement of liver function. Once portal hypertension is established the prognosis is poor; in one series 20% of affected children died as a direct result of the liver disease, with a mean survival of only 4-5 years,3 and in this and other series an excess of respiratory deaths has been noted in children with liver disease.2 Although portal systemic shunting may be palliative, liver transplantation offers the only potentially curative treatment for portal hypertension. It has seldom been attempted for several reasons, however; firstly, it is difficult to In spite of the pancreatic enzyme supplements they were receiving, to maintain therapeutic concentrations of cyclosporin all the children required high total doses (10-35 mg/kg/day) given in three doses daily. Even so, in patient 5 it proved impossible to maintain adequate concentrations of cyclosporin so he was changed to the better absorbed immunosuppressant FK506 (Fujisawa, Munich, Germany).
Among the four children with normal graft function nutrition was greatly improved (table 2) in three. Patient 1 unfortunately became anorexic, but started to gain weight after the insertion of a gastrostomy feeding tube. A surprising and gratifying outcome was a striking subjective improvement in respiratory function in all the children; they showed remarkably improved exercise tolerance and decreased cough and sputum production. Respiratory infection did not increase in spite of the ne-ed for immunosuppression. Formal pulmonary function tests in four children showed improved indices in three and only a slight decrease in patient 1 27 months after transplantation (table 3) . Another unexpected benefit was a remission in diabetes in patient 4; she stopped taking insulin seven weeks after transplantation and was still in remission 14 months later.
Discussion
The liver disease of cystic fibrosis is thought to result primarily from the accumulation of abnormally tenacious bile in the intrahepatic ducts, which impedes bile flow and causes injury to the biliary epithelium and consequent biliary cirrhosis. In addition, there is increased faecal bile acid loss and this results in the production ofhydrophobic bile acids which are potentially hepatotoxic. The The mean age at presentation was 9-8 years and in most the first sign to be detected was enlargement of the liver or spleen, or both. Although in that series only 7-8% of the children died as a direct result of their liver disease, there was an increased mortality in teenagers with liver disease, probably due to exacerbation of the lung problems. Feigelson et al reported the long term outcome of 450 children with cystic fibrosis, among whom 31 (7%) developed multilobular cirrhosis at a mean age of 7 years.3 Twenty children had varices and seven had surgical treatment for their portal hypertension (five a portocaval shunt, one a splenectomy, and one triple transplantation). Six children died of liver complications after a mean survival of only 4-5 years, and 10 died from lung complications. Stem et al reported that, of five children who received portal systemic shunts for variceal bleeding, three were alive from one to nine years after the operation and two died at a mean of eight years.6 Others, such as Tyson et al,9 have reported much poorer results, with six of 17 children dying within two months of the operation. Portal systemic shunting may be effective in relieving bleeding, but requires a major operation, may precipitate encephalopathy, and greatly complicates any subsequent attempt at liver transplantation.
There are few reports to date of the outcome of patients with cystic fibrosis after liver transplantation. Cox described five children and five adults who had only mild to moderate lung disease and received liver grafts; three patients died from infective complications, as a result of pseudomonas in two and aspergillus in one, but among the surviving patients pulmonary function improved in five.'0 Mieles et al reported four children and five adults; two died from problems directly related to the operation but, among the seven patients who survived, pulmonary function either improved or remained stable. I I These two groups raised the question of whether colonisation of the lungs with pseudomonas increased the risk of death from pneumonia after transplantation and whether postoperative management should be modified. We have not seen an increase in postoperative morbidity from pulmonary infection after successful liver transplantation. Indeed, the most impressive outcome in this small series of children has been the improvement in subjective pulmonary symptoms. All the children had greatly improved exercise tolerance and decreased sputum production. There are several possible reasons for this unexpected benefit. Liver cirrhosis with portal hypertension causes abdominal distension and diaphragmatic splinting, which is relieved after transplantation; the liver disease is associated with intrapulmonary shunting and pulmonary oedema, which contributes to the lung problems; and malnutrition reduces resistance to infection. It is also possible that immunosuppressive treatment, perhaps particularly with cyclosporin, may exert a specific beneficial effect by blocking cytokine production and thereby inhibiting inflammatory processes in the airways. '2 It was surprising that the diabetes of patient 4 showed a prolonged remission after liver transplantation as the cause of diabetes associated with cystic fibrosis seems primarily to be the mechanical disruption and destruction of pancreatic tissue rather than an autoimmune process. It has also been suggested that liver disease may unmask subclinical diabetes as the ability of a damaged liver to deal with a glucose load is impaired. '3 In conclusion, we suggest that children with cystic fibrosis complicated by hepatic cirrhosis and portal hypertension, but with relatively well preserved lung function, should be considered for liver transplantation once varices are present. Such children are at constant risk from variceal bleeding and worsening of nutritional and respiratory status may lead to premature death from pulmonary complications. Liver transplantation remains a high risk procedure, but in cystic fibrosis, when successful, it is not attended with increased infective or pulmonary morbidity. Not only is the portal hypertension relieved and the danger of bleeding removed, but there may also be striking benefits in improved pulmonary function, nutrition, and in general wellbeing. cystic fibrosis. 
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